Longevity plasma cell capable of secreting PD-1 antibody as well as preparation method and application of longevity plasma cell

Abstract

The invention discloses a longevity plasma cell capable of secreting a PD-1 antibody as well as a preparation method and application of the longevity plasma cell. The method specifically comprises thefollowing steps: integrating a PD-1 antibody gene into a B cell at a fixed point to obtain a genetically engineered B cell; and inducing the genetically engineered B cell into a longevity plasma cellsecreting a PD-1 antibody. The prepared longevity plasma cell capable of secreting the PD-1 antibody has typical phenotype and transcription characteristics of the longevity plasma cell; in addition,a large number of PD-1 antibodies can be continuously secreted, PD-1 antibody drug-mediated tumor immunotherapy is expected to be replaced, Meanwhile, a new thought is provided for tumor adoptive cellular immunotherapy. Moreover, the antibody gene is introduced into B cells to be induced into long-life plasma cells capable of continuously secreting a large number of antibodies; the new thought therapy for treating the long-life plasma cell transfused patient not only can be used for treating various tumors, but also has a wide application prospect in various infectious diseases such as AIDS (acquired immune deficiency syndrome) and chronic viral hepatitis B, and protein-deficient diseases such as hemophilia.

Description

technical field [0001] The invention belongs to the technical field of biomedicine. More specifically, it relates to a long-lived plasma cell secreting PD-1 antibody and its preparation method and application. Background technique [0002] Because of its unclear pathogenesis and high mortality rate, tumors are extremely difficult to treat. At present, the traditional treatment methods include surgical resection, radiotherapy, and chemical drug treatment. The traditional treatment methods all have defects such as high toxicity and side effects, unclear drug targets, and easy tumor recurrence. Immune checkpoint blockade therapy has a significant anti-tumor effect. Among them, immune checkpoint blockade therapy targeting PD-1 has made a major breakthrough in the field of tumor immunotherapy, such as the PD-1 blocking antibody nivolumab and Pai Monoclonal antibody. These antibodies inhibit the exhaustion of T cells by blocking the binding of PD-1 and its ligand PD-L1, thereby...

AI Technical Summary

Problems solved by technology

However, efficiency and safety are the focus of genetic engineering technology. The gene editing efficiency of existing gene editing methods on human primary B cells, especially the knock-in efficiency of large fragments of foreign genes, has always been very low.

So far, no relevant studies and reports have been seen

Images